CoChat
Sign Up
Cited by 106

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Reduction of the cerebrovascular volume in a transgenic mouse model of Alzheimer's disease

Bourasset, Fanchon, Ouellet, Mélissa, Tremblay, Cyntia, Julien, Carl, Do, Tuan Minh, Oddo, Salvatore, LaFerla, Frank, Calon, Frédéric·2009·Neuropharmacology
DOI 10.1016/j.neuropharm.2009.01.006
Open this paper in CoChat — free account

Abstract

Combined evidence from neuroimaging and neuropathological studies shows that signs of vascular pathology and brain hypoperfusion develop early in Alzheimer's disease (AD). To investigate the functional implication of these abnormalities, we have studied the cerebrovascular volume and selected markers of blood-brain barrier (BBB) integrity in 11-month-old 3 x Tg-AD mice, using the in situ brain perfusion technique. The cerebrovascular volume of distribution of two vascular space markers, [3H]-inulin and [14C]-sucrose, was significantly lower (-26% and -27%, respectively; p < 0.01) in the brain of 3 x Tg-AD mice compared to non-transgenic littermates. The vascular volume reduction was significant in the hippocampus (p < 0.01), but not in the frontal cortex and cerebellum. However, the brain transport coefficient (Clup) of [14C]-D-glucose (1 microM) and [3H]-diazepam was similar between 3xTg-AD mice and controls, suggesting no difference in the functional integrity of the BBB. We also report a 32% increase (p < 0.001) in the thickness of basement membranes surrounding cortical microvessels along with a 20% increase (p < 0.05) of brain collagen content in 3xTg-AD mice compared to controls. The present data indicate that the cerebrovascular space is reduced in a mouse model of Abeta and tau accumulation, an observation consistent with the presence of cerebrovascular pathology in AD.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.neuropharm.2009.01.006

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 31

  1. Beckmann, 2003, Age-dependent cerebrovascular abnormalities and blood flow disturbances in APP23 mice modeling Alzheimer's disease, J. Neurosci., 23, 8453, 10.1523/JNEUROSCI.23-24-08453.2003 · DOI
  2. Bornstein, 1980, Structurally distinct collagen types, Annu. Rev. Biochem., 49, 957, 10.1146/annurev.bi.49.070180.004521 · DOI
  3. Bouras, 2006, Stereologic analysis of microvascular morphology in the elderly: Alzheimer disease pathology and cognitive status, J. Neuropathol. Exp. Neurol., 65, 235, 10.1097/01.jnen.0000203077.53080.2c · DOI
  4. Bourasset, 2003, Evidence for an active transport of morphine-6-beta-d-glucuronide but not P-glycoprotein-mediated at the blood–brain barrier, J. Neurochem., 86, 1564, 10.1046/j.1471-4159.2003.01990.x · DOI
  5. Bradley, 2002, Cerebral perfusion SPET correlated with Braak pathological stage in Alzheimer's disease, Brain, 125, 1772, 10.1093/brain/awf185 · DOI
  6. Buee, 1994, Pathological alterations of the cerebral microvasculature in Alzheimer's disease and related dementing disorders, Acta Neuropathol. (Berl.), 87, 469, 10.1007/BF00294173 · DOI
  7. Cummings, 2004, The role of positron emission tomography in the diagnosis of Alzheimer's disease, J. Am. Geriatr. Soc., 52, 467, 10.1111/j.1532-5415.2004.52125_2.x · DOI
  8. Dagenais, 2000, Development of an in situ mouse brain perfusion model and its application to mdr1a P-glycoprotein-deficient mice, J. Cereb. Blood Flow Metab., 20, 381, 10.1097/00004647-200002000-00020 · DOI
  9. Hawkins, 2008, Pathophysiology of the blood–brain barrier: animal models and methods, Curr. Top. Dev. Biol., 80, 277, 10.1016/S0070-2153(07)80007-X · DOI
  10. Herzig, 2006, Mechanism of cerebral beta-amyloid angiopathy: murine and cellular models, Brain Pathol., 16, 40, 10.1111/j.1750-3639.2006.tb00560.x · DOI
  11. Hooijmans, 2007, Changes in cerebral blood volume and amyloid pathology in aged Alzheimer APP/PS1 mice on a docosahexaenoic acid (DHA) diet or cholesterol enriched Typical Western Diet (TWD), Neurobiol. Dis., 28, 16, 10.1016/j.nbd.2007.06.007 · DOI
  12. Jellinger, 2005, Prevalence and pathogenic role of cerebrovascular lesions in Alzheimer disease, J. Neurol. Sci., 229–230, 37, 10.1016/j.jns.2004.11.018 · DOI
  13. Johnson, 2005, Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience, Radiology, 234, 851, 10.1148/radiol.2343040197 · DOI
  14. Julien, C., Tremblay, C., Phivilay, A., Berthiaume, L., Emond, V., Julien, P., Calon, F. High-fat diet aggravates amyloid-beta and tau pathologies in the 3×Tg-AD mouse model. Neurobiol. Aging, in press, doi:10.1016/j.neurobiolaging.2008.08.022 [published on-line October 14, 2008]. · DOI · Paper page
  15. Kalaria, 2002, Small vessel disease and Alzheimer's dementia: pathological considerations, Cerebrovas. Dis., 13, 48, 10.1159/000049150 · DOI
  16. Kalaria, 1995, Increased collagen content of cerebral microvessels in Alzheimer's disease, Brain Res., 705, 349, 10.1016/0006-8993(95)01250-8 · DOI
  17. Lee, 2005, Stereological analysis of microvascular parameters in a double transgenic model of Alzheimer's disease, Brain Res. Bull., 65, 317, 10.1016/j.brainresbull.2004.11.024 · DOI
  18. Mueggler, 2002, Compromised hemodynamic response in amyloid precursor protein transgenic mice, J. Neurosci., 22, 7218, 10.1523/JNEUROSCI.22-16-07218.2002 · DOI
  19. Niwa, 2002, Cerebrovascular autoregulation is profoundly impaired in mice overexpressing amyloid precursor protein, Am. J. Physiol. Heart Circ. Physiol., 283, H315, 10.1152/ajpheart.00022.2002 · DOI · Paper page
  20. Niwa, 2002, Alterations in cerebral blood flow and glucose utilization in mice overexpressing the amyloid precursor protein, Neurobiol. Dis., 9, 61, 10.1006/nbdi.2001.0460 · DOI · Paper page
  21. Paris, 2004, Impaired angiogenesis in a transgenic mouse model of cerebral amyloidosis, Neurosci. Lett., 366, 80, 10.1016/j.neulet.2004.05.017 · DOI
  22. Paris, 2004, Nilvadipine antagonizes both Abeta vasoactivity in isolated arteries, and the reduced cerebral blood flow in APPsw transgenic mice, Brain Res., 999, 53, 10.1016/j.brainres.2003.11.061 · DOI
  23. Paul, 2007, Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer's disease, J. Exp. Med., 204, 1999, 10.1084/jem.20070304 · DOI · Paper page
  24. Qutub, 2005, Glucose transport to the brain: a systems model, Brain Res. Brain Res. Rev., 49, 595, 10.1016/j.brainresrev.2005.03.002 · DOI
  25. Rockenstein, 2005, Amelioration of the cerebrovascular amyloidosis in a transgenic model of Alzheimer's disease with the neurotrophic compound cerebrolysin?, J. Neural Transm., 112, 269, 10.1007/s00702-004-0181-4 · DOI
  26. Scholz, 1938, Studien zur Pathologie der Hirngefässe II; Die drusige Entartung der Hirnarterien und — capillaren, Neurol. Psychiatr., 162, 694, 10.1007/BF02890989 · DOI
  27. Tong, 2005, Vascular remodeling versus amyloid beta-induced oxidative stress in the cerebrovascular dysfunctions associated with Alzheimer's disease, J. Neurosci., 25, 11165, 10.1523/JNEUROSCI.4031-05.2005 · DOI
  28. Tremblay, 2007, Biochemical characterization of Abeta and tau pathologies in mild cognitive impairment and Alzheimer's disease, J. Alzheimers Dis., 12, 377, 10.3233/JAD-2007-12411 · DOI
  29. Wang, 2006, Vascular volume and blood–brain barrier permeability measured by dynamic contrast enhanced MRI in hippocampus and cerebellum of patients with MCI and normal controls, J. Magn. Reson. Imaging, 24, 695, 10.1002/jmri.20669 · DOI · Paper page
  30. Zarow, 1997, Vascular basement membrane pathology and Alzheimer's disease, Ann. N. Y. Acad. Sci., 826, 147, 10.1111/j.1749-6632.1997.tb48467.x · DOI
  31. Zlokovic, 2005, Neurovascular mechanisms of Alzheimer's neurodegeneration, Trends Neurosci., 28, 202, 10.1016/j.tins.2005.02.001 · DOI · Paper page

Cited by

Sorted by citations

Metadata

Authors
Bourasset, F., Ouellet, M., Tremblay, C., Julien, C., Do, T. M., Oddo, S., LaFerla, F., & Calon, F.
Venue
Neuropharmacology
Publisher
Elsevier BV
Published
2009-03
Volume
56
Issue
4
Pages
808-813
ISSN
0028-3908
DOI
10.1016/j.neuropharm.2009.01.006
Cited by
106
References
10
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review